Skip to content

The evaluation test of glucose tolerance change and intestinal environmental change by intake of barley

The evaluation test of glucose tolerance change and intestinal environmental change by intake of barley - The evaluation test of glucose tolerance change and intestinal environmental change by intake of barley

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000023675
Enrollment
24
Registered
2016-08-18
Start date
2016-08-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Test food intake for 4 weeks - Washout 4 weeks - Control food intake for 4 weeks Control food intake for 4 weeks - Washout 4 weeks - Test food intake for 4 weeks

Sponsors

CPCC Company Limited
Lead Sponsor
Hakubaku co.,Ltd.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Males and females aged 50 to 69 years old. 2) Subjects whose body mass index (BMI) is included between 18 kg/m2 to less than 25 kg/m2. 3)Subjects whose fasting blood glucose level is under 109 mg/dL. 4) Subjects who don't take fermented foods, dietary fibers and supplements regularly. 5) Subjects who show understanding of the study procedures and agreement with participating the study by written informed consent prior to the study.

Exclusion criteria

Exclusion criteria: 1)Subjects who didn't undergo abdominal surgical operation within 6 month before test start. 2)Subjects who didn't take antibiotics for 1 month or more within 6 month before test start. 3)Subjects who have allergy to test food. 4)Smokers 5)Subjects whose consort or partner also participates to same clinical test. 6)Subjects who plan big change of lifestyle during test period. 7)Subjects with tendency of chronic diarrhea. 8)Subjects who considered unfitness for the test because of having previous and/or current medical history of serious disease of liver, kidney and heart. 9)Subjects who suspected chronic or serious infectious disease. 10)Premenopausal women. 11)Subjects who participated the other clinical test within 1 month before test start. 12)Subjects who donated over 200 mL blood and/or blood components within the last one month to the current study. 13)Males who donated over 400 mL blood within the last three month to the current study. 14)Females who donated over 400 mL blood within the last four month to the current study. 15) Males who will be collected over 1200 mL blood, when the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study. 16) Females who will be collected over 800 mL blood, when the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study. 17)Others who have been determined ineligible by principal investigator or sub-investigator.

Design outcomes

Primary

MeasureTime frame
Area under the curve of blood glucose and blood insulin in glucose tolerance test during 2weeks and 4 weeks of consumption

Secondary

MeasureTime frame
1)Incremental area under the curve of blood glucose and blood insulin in glucose tolerance test during 2weeks and 4 weeks of consumption 2)Blood glucose and blood insulin in glucose tolerance test during 2weeks and 4 weeks of consumption 3)Improving effect of intestinal environment (bowel movement, intestinal microflora, intestinal metabolite) during 2weeks and 4 weeks of consumption 4)Questionnaire of physical feeling during 2weeks and 4 weeks of consumption

Countries

Japan

Contacts

Public ContactMakoto Ichinohe

CPCC Company Limited Plan Sales Department

cpcc-contact@cpcc.co.jp03-5297-3112

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026